Baseline Characteristics and Substance Use Among People Who Inject Drugs With Evidence of Active Use in HPTN 103/PURPOSE 4: A Phase 2 Study of Twice-Yearly Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis

Conference Reports for NATAP

IDSA
ID Week 2026
October 21-24
Washington, DC


Baseline Characteristics and Substance Use Among People Who Inject Drugs With Evidence of Active Use in HPTN 103/PURPOSE 4: A Phase 2 Study of Twice-Yearly Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis

	IDSA Oct 21-24 Wash DC